News
New RUBY readout buoys GSK’s Jemperli in endometrial cancer
GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i
